Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Rosarelis Torres"'
Autor:
Rosarelis Torres, Sandra Smieszek, Changfu Xiao, Emily Czeisler, Christos Polymeropoulos, Gunther Birznieks, Mihael Polymeropoulos
Publikováno v:
SLEEP. 46:A282-A282
Introduction Iloperidone, a dopamine D2 receptor and serotonin 5HT2A receptor antagonist, was evaluated for the treatment of acute manic and mixed episodes associated with bipolar I disorder in adults in a phase 3 clinical trial. A core symptom of bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5eb3dd09caccef6ba7223ab102eadb4d
https://doi.org/10.1093/sleep/zsad077.0642
https://doi.org/10.1093/sleep/zsad077.0642
Simulated driving performance in healthy adults after night-time administration of 20 mg tasimelteon
Autor:
Gunther Birznieks, Rosarelis Torres, Changfu Xiao, Michaela Fisher, Mihael H. Polymeropoulos, Christos Polymeropoulos, Gary G Kay
Publikováno v:
Journal of sleep research. 31(1)
An impairment in next day driving performance has been reported for almost every drug currently United States Food and Drug Administration (FDA) approved for improvement of sleep in chronic and transient insomnia. Tasimelteon, a melatonin receptor ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b9169f6dd6a113057cd301fe842e393
https://pubmed.ncbi.nlm.nih.gov/34152055
https://pubmed.ncbi.nlm.nih.gov/34152055
Publikováno v:
The Journal of Clinical Pharmacology. 55:1004-1011
Tasimelteon ([1R-trans]-N-[(2-[2,3-dihydro-4-benzofuranyl] cyclopropyl) methyl] propanamide), a novel dual melatonin receptor agonist that demonstrates specificity and high affinity for melatonin receptor types 1 and 2 (MT1 and MT2 receptors), is the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abb3f17619f74f13d9670f778c5ee2ea
https://doi.org/10.1002/jcph.507
https://doi.org/10.1002/jcph.507
Publikováno v:
Journal of Clinical Pharmacology
Tasimelteon is a circadian regulator that resets the master clock in the suprachiasmatic nuclei of the hypothalamus by binding to both melatonin MT1 and MT2 receptors making it a dual melatonin receptor agonist. Tasimelteon has been approved by the U
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ee60b78c383ad5e58adfe4922bea39d
https://doi.org/10.1002/jcph.440
https://doi.org/10.1002/jcph.440
Autor:
Louis Licamele, Mihael H. Polymeropoulos, Dennis M Fisher, Changfu Xiao, Marlene A. Dressman, Steven W. Lockley, Rosarelis Torres, Christian Lavedan, Erin E. Flynn-Evans, Joseph T. Hull
Publikováno v:
Lancet (London, England). 386(10005)
Summary Background Most totally blind people have non-24-hour sleep–wake disorder (non-24), a rare circadian rhythm disorder caused by an inability of light to reset their circadian pacemaker. In two consecutive placebo-controlled trials (SET and R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3345f6d30a89725520fc7aeb83614bf
https://pubmed.ncbi.nlm.nih.gov/26554081
https://pubmed.ncbi.nlm.nih.gov/26554081
Publikováno v:
American journal of therapeutics. 22(5)
Tasimelteon is a novel dual melatonin receptor agonist and is the first treatment approved by the US Food and Drug Administration for Non-24-Hour Sleep-Wake Disorder. This study was conducted to assess the absolute bioavailability of tasimelteon and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dfea2861a5f32e87c6a8f25bb252cc5
https://pubmed.ncbi.nlm.nih.gov/25658956
https://pubmed.ncbi.nlm.nih.gov/25658956
Publikováno v:
Journal of clinical psychopharmacology. 28(2 Suppl 1)
Iloperidone is an atypical antipsychotic in development for the treatment of schizophrenia. This report examines efficacy results from three 6-week, randomized, double-blind, placebo- and active comparator-controlled studies in patients with schizoph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4136b0ec4890247959e240c991ef019c
https://pubmed.ncbi.nlm.nih.gov/18334911
https://pubmed.ncbi.nlm.nih.gov/18334911
Autor:
Amalia Dutra, Stephanie Buchholtz, Elisabeth Leroy, Robert L. Nussbaum, Christian Lavedan, Mihael H. Polymeropoulos, Anindya Dehejia, Rosarelis Torres
Publikováno v:
Genomics. 54:173-175
The beta-synuclein protein is highly homologous to the alpha-synuclein protein for which two mutations were reported in some familial cases of Parkinson disease. It has been shown that both alpha- and beta-synucleins may be able to inhibit phospholip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bbd379b8276c1e510b14bb49fc312a5
https://doi.org/10.1006/geno.1998.5556
https://doi.org/10.1006/geno.1998.5556
Autor:
Susan E. Ide, Anindya Dehejia, Mihael H. Polymeropoulos, Alexander S. Baras, Rosarelis Torres
Publikováno v:
DNA research : an international journal for rapid publication of reports on genes and genomes. 6(5)
In the course of our analysis of genomic sequence from the human chromosome 4p16.1 region harboring both the Wolfram and Ellis van Creveld syndrome genes we have identified a sequence with high homology (98% at the amino acid level) to the rat cDNA c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b25cfd78dc9ce75dabb602eb24aae41e
https://pubmed.ncbi.nlm.nih.gov/10574460
https://pubmed.ncbi.nlm.nih.gov/10574460
Publikováno v:
DNA research : an international journal for rapid publication of reports on genes and genomes. 5(6)
The Collapsin Response Mediator Protein-1 (CRMP-1) is a brain specific protein considered to be involved in the collapsin-induced growth cone collapse during neural development. CRMP-1 belongs to the Unc-33 gene family. Here we report the genomic str
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33babe5736e0d3f3989019148c4477fa
https://pubmed.ncbi.nlm.nih.gov/10048489
https://pubmed.ncbi.nlm.nih.gov/10048489